TRIP4

TRIP4 (ASC-1) is a transcriptional coactivator that occupies target gene promoters and drives oncogenic transcriptional programs across multiple cancers (PMID:34648907, PMID:28899685, PMID:40180167). Its C-terminal ASCH domain binds both ssDNA and dsDNA in a sequence-independent manner through two adjacent positively charged surface patches that engage the 5'- and 3'-ends of DNA, providing the structural basis for chromatin association (PMID:38870938). Through direct promoter occupancy TRIP4 activates transcription of DDIT4 to engage mTOR signaling in glioma (PMID:34648907), COX-2 and iNOS in synergy with the co-activator p300 in melanoma (PMID:28899685), hTERT in cervical cancer where it also supports PI3K/AKT and MAPK/ERK signaling and Rad51-dependent radioresistance (PMID:30905820), and GATA2, which acts as a key downstream effector of TRIP4-driven cervical cancer progression (PMID:40180167). TRIP4 activity is gated by the E3 ligase RNF25, which catalyzes non-degradative ubiquitination at lysine 135 to disrupt TRIP4–p65 interactions, liberating p65 to activate NF-κB signaling and anti-apoptotic effectors cIAP2 and Bcl-2 in renal cell carcinoma (PMID:40765826). Beyond these promoter-specific and regulatory findings, the broader chromatin and RNA-processing context of TRIP4 within the ASC-1 complex is not characterized in the available corpus.

1. 2017 Medium

   Established that TRIP4 acts as a direct, promoter-anchored transcriptional activator rather than only an indirect signaling modulator, by showing it occupies COX-2 and iNOS promoters in synergy with p300.

   Evidence ChIP, co-activator interaction studies, and siRNA knockdown in melanoma in vitro and in vivo models

   PMID:28899685

   Open questions at the time

   • Does not define the DNA sequence or structural determinants of TRIP4 promoter binding
   • Mechanism of p300 recruitment versus NF-κB-mediated indirect activation not separated
2. 2019 Medium

   Extended TRIP4's promoter-binding role to hTERT regulation and linked it to PI3K/AKT, MAPK/ERK signaling and DNA-damage response, establishing a role in cancer cell radioresistance.

   Evidence siRNA knockdown, Western blot, ChIP, and xenograft model in cervical cancer

   PMID:30905820

   Open questions at the time

   • Whether signaling changes are direct or downstream of altered transcription is unresolved
   • No structural basis for hTERT promoter binding
3. 2021 Medium

   Defined a specific TRIP4 promoter target (DDIT4, −196 to −11) and connected its transcriptional output to mTOR signaling under HIF1α modulation, giving a concrete gene-to-pathway axis.

   Evidence ChIP, promoter reporter assays, and knockdown/overexpression rescue in glioma in vitro and in vivo

   PMID:34648907

   Open questions at the time

   • How HIF1α modulates TRIP4 activity mechanistically is not defined
   • Direct versus cofactor-dependent DDIT4 binding not resolved
4. 2021 Low

   Placed TRIP4 within the ASC-1 ribonucleoprotein complex and linked a loss-of-function variant to altered RNA processing and exosome activity, broadening its role beyond promoter-bound transcription.

   Evidence Exome sequencing and proteomic profiling of patient fibroblasts

   PMID:34075209

   Open questions at the time

   • Correlative proteomics in patient cells without direct mechanistic reconstitution
   • Composition and function of the ASC-1 complex not mapped
   • Causal link between variant and RNA-processing defect not established
5. 2024 High

   Provided the structural mechanism for TRIP4 chromatin engagement, showing the ASCH domain binds DNA sequence-independently via two positively charged patches contacting the DNA ends.

   Evidence Crystal structure determination, biochemical binding assays, and site-directed mutagenesis of human TRIP4

   PMID:38870938

   Open questions at the time

   • Does not explain how sequence-independent binding achieves promoter specificity in cells
   • Role of the N-terminal zinc-finger domain in DNA or partner binding not addressed
6. 2025 Medium

   Identified GATA2 as a key direct downstream effector of TRIP4, with GATA2 overexpression rescuing the growth defect of TRIP4 knockdown, providing an epistatic mechanism for TRIP4-driven cervical cancer progression.

   Evidence Pulldown, ChIP, and knockdown/overexpression rescue experiments

   PMID:40180167

   Open questions at the time

   • Single-lab epistasis without independent validation
   • Whether GATA2 is the sole effector is unknown
7. 2025 Medium

   Revealed post-translational control of TRIP4 by RNF25, which ubiquitinates K135 non-degradatively to disrupt TRIP4–p65 binding and unleash NF-κB-driven anti-apoptotic signaling, defining a regulatory switch for TRIP4 function.

   Evidence Co-immunoprecipitation, ubiquitination assay, and K135 site-directed mutagenesis in renal cell carcinoma

   PMID:40765826

   Open questions at the time

   • Single-lab finding without reciprocal genetic validation in other contexts
   • How K135 ubiquitination structurally disrupts the p65 interface is not defined
   • Whether other E3 ligases regulate TRIP4 is unknown

• How TRIP4's sequence-independent DNA binding is targeted to specific promoters, and how its transcriptional coactivator role integrates with its ASC-1 complex RNA-processing function, remain unresolved.
• No mechanism linking sequence-independent ASCH–DNA binding to promoter specificity
• Composition and stoichiometry of the ASC-1 complex not mapped in the corpus
• Cellular localization dynamics of TRIP4 not characterized